CDNA logo

CareDx Inc. (CDNA)

$26.18

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CDNA

Market cap

$1.35B

EPS

-0.16

P/E ratio

--

Price to sales

2.6

Dividend yield

--

Beta

2.487772

Price on CDNA

Previous close

$23.48

Today's open

$23.93

Day's range

$23.93 - $26.26

52 week range

$10.96 - $26.26

Profile about CDNA

CEO

John W. Hanna

Employees

765

Headquarters

Brisbane, CA

Exchange

NASDAQ Global Market

Shares outstanding

51659481

Issue type

Common Stock

CDNA industries and sectors

Healthcare

Medical Diagnostics & Screening

News on CDNA

CareDx's CEO Sells 17K Shares

The CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15. The transaction represented 2.7% of John Hanna's direct holdings.

news source

The Motley Fool • Jun 22, 2026

news preview

CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?

CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

news source

Zacks Investment Research • Jun 19, 2026

news preview

CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced its participation at the American Transplant Congress (ATC) 2026, taking place June 20–24 in Boston, Massachusetts. Real-world clinical use and scientific advancements involving AlloSure® Kidne.

news source

Business Wire • Jun 18, 2026

news preview

CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multi-center study, in the Journal of the American Society of Nephrology (JASN). The se.

news source

Business Wire • Jun 16, 2026

news preview

CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans

CareDx NASDAQ: CDNA executives outlined the company's strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.

news source

MarketBeat • Jun 9, 2026

news preview

CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Jun 8, 2026

news preview

Baron Discovery Fund Q1 2026: Who Moved The Needle

In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. Advanced Energy Industries, Inc.'s stock rose during the quarter as the market began to appreciate the strength that the company would see in both its data center and semiconductor end markets. Baron Discovery Fund sold its investment in Intapp, Inc. in the quarter as the team believes that its other software holdings have better overall competitive advantages.

news source

Seeking Alpha • Jun 8, 2026

news preview

CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx NASDAQ: CDNA executives outlined the company's growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration.

news source

MarketBeat • Jun 7, 2026

news preview

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,.

news source

Business Wire • May 20, 2026

news preview

CareDx Announces Dismissal of 2021 Qui Tam Suit

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter. Ther.

news source

Business Wire • May 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in CareDx Inc.

Open an M1 investment account to buy and sell CareDx Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CDNA on M1